Company intelligence / Profile preview

Iotron Medical

Saskatoon, Saskatchewan, Canadaiotronmedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

Iotron Medical is the world’s first commercial supplier of high-specific activity copper‑67 (Cu‑67), a therapeutic radioisotope with broad potential in cancer theranostics. Their proprietary electron beam accelerator technology enables reliable, high-purity production of Cu‑67, which is distributed to research institutions and radiopharma companies across North America and Europe. The company is expanding its isotope portfolio using photonuclear technology

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalRadiopharmaceutical precursor (Copper-67)
Industry: Chemicals & Materials

Drug pipeline

1 asset

copper-67

Commercial

Indications: Cancer

Partnerships

Canadian Nuclear Isotope Council memberResearch institutions and radiopharma companies as customers/distribution partners

Beyond the preview

Go deeper on Iotron Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iotron Medical.

Explore the full profile